This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1999 Jan 13;281(2):180-1.

doi: 10.1001/jama.281.2.180.

When should patients with heterozygous familial hypercholesterolemia be treated?

B M Rifkind, B Schucker, D J Gordon

PMID: 9917123
DOI: 10.1001/jama.281.2.180

Editorial

When should patients with heterozygous familial hypercholesterolemia be treated?

B M Rifkind et al. JAMA. 1999.

. 1999 Jan 13;281(2):180-1.

doi: 10.1001/jama.281.2.180.

Authors

B M Rifkind, B Schucker, D J Gordon

PMID: 9917123
DOI: 10.1001/jama.281.2.180

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.
Stein EA, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, Jacobson MS, Brewster TG, Hopkins P, Davidson M, Graham K, Arensman F, Knopp RH, DuJovne C, Williams CL, Isaacsohn JL, Jacobsen CA, Laskarzewski PM, Ames S, Gormley GJ. Stein EA, et al. JAMA. 1999 Jan 13;281(2):137-44. doi: 10.1001/jama.281.2.137. JAMA. 1999. PMID: 9917116 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems